The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...

The significance of this is that it brings about the ability to obtain FDA approval for this AAV gene therapy without the need to run a phase 3 study. Even better, it has another positive worth ...

Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...

Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.

Months after disclosing significant layoffs across its North Carolina operations, Pfizer (NYSE: PFE) plans to eliminate more ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

This year’s conference, in Chicago, showcased a diverse array of practice-changing data across multiple ophthalmic specialties, including advances in cataract surgery, glaucoma management, and retinal ...

Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs ...

RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.